Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
AssigneeJanssen Pharmaceutica NV
InventorsChristian Andrew Baumann, Michael David Gaul, Dana L. Johnson, Robert W. Tuman
Life of this patent
Estimating the term…
Abstract
The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
Claims15
A method of treating a disorder selected from the group consisting of acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of (1) a FLT3 kinase inhibitor that is:
- or a pharmaceutically acceptable salt thereof and (2) a farnesyl transferase inhibitor that is (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, or a pharmaceutically acceptable acid addition salt thereof.
A method of treating a disorder selected from the group consisting of acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of (1) a first pharmaceutical composition comprising a FLT3 kinase inhibitor that is:
- or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and (2) a second pharmaceutical composition comprising a farnesyl transferase inhibitor that is (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.
A method of treating a disorder selected from the group consisting of acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a FLT3 kinase inhibitor that is:
- or a pharmaceutically acceptable salt thereof, a farnesyl transferase inhibitor that is (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.